Identification of Putative Serum Autoantibodies Associated with Post-Acute Sequelae of COVID-19 via Comprehensive Protein Array Analysis
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26041751 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Yasuyoshi Hatayama und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Virology III, National Institute of Infectious Diseases, Musashimurayama 208-0011, Japan. Hauptthemen laut MEDLINE: Autoantibodies, COVID-19. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Science Foundation.
Abstract (Originalsprache)
Post-acute sequelae of SARS-CoV-2 infection (PASC), commonly known as “Long COVID”, represents a significant clinical challenge characterized by persistent symptoms following acute COVID-19 infection. We conducted a comprehensive retrospective cohort study to identify serum autoantibody biomarkers associated with PASC. Initial screening using a protein bead array comprising approximately 20,000 human proteins identified several candidate PASC-associated autoantibodies. Subsequent validation by enzyme-linked immunosorbent assay (ELISA) in an expanded cohort—consisting of PASC patients, non-PASC COVID-19 convalescents, and pre-pandemic healthy controls—revealed two promising biomarkers: autoantibodies targeting PITX2 and FBXO2. PITX2 autoantibodies demonstrated high accuracy in distinguishing PASC patients from both non-PASC convalescents (area under the curve [AUC] = 0.891) and healthy controls (AUC = 0.866), while FBXO2 autoantibodies showed moderate accuracy (AUC = 0.762 and 0.786, respectively). Notably, the levels of these autoantibodies were associated with several PASC symptoms, including fever, dyspnea, palpitations, loss of appetite, and brain fog. The identification of PITX2 and FBXO2 autoantibodies as biomarkers not only enhances our understanding of PASC pathophysiology but also provides promising candidates for further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Virology III, National Institute of Infectious Diseases, Musashimurayama 208-0011, Japan.
- Department of Microbiology, Yokohama City University School of Medicine, Yokohama 236-0004, Japan.
- Research Center for Influenza and Respiratory Viruses, National Institute of Infectious Diseases, Musashimurayama 208-0011, Japan.
- Advanced Medical Research Center, Yokohama City University, Yokohama 236-0004, Japan.
- Hirahata Clinic, Tokyo 150-0002, Japan.
- Department of Health Science, Gunma Paz University Graduate School of Health Sciences, Takasaki 370-0006, Japan.
ORCID-Profile: Hideaki Kato
Förderung
- Takeda Science Foundation
Zitieren
APA
Hatayama, Y., Miyakawa, K., Kimura, Y., Horikawa, K., Hirahata, K., Kimura, H., Kato, H., Goto, A., & Ryo, A. (2025). Identification of Putative Serum Autoantibodies Associated with Post-Acute Sequelae of COVID-19 via Comprehensive Protein Array Analysis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26041751
Vancouver
Hatayama Y, Miyakawa K, Kimura Y, Horikawa K, Hirahata K, Kimura H, et al. Identification of Putative Serum Autoantibodies Associated with Post-Acute Sequelae of COVID-19 via Comprehensive Protein Array Analysis. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26041751
BibTeX
@article{Hatayama2025,
author = {Hatayama, Yasuyoshi and Miyakawa, Kei and Kimura, Yayoi and Horikawa, Kazuo and Hirahata, Kouichi and Kimura, Hirokazu and Kato, Hideaki and Goto, Atsushi and Ryo, Akihide},
title = {Identification of Putative Serum Autoantibodies Associated with Post-Acute Sequelae of COVID-19 via Comprehensive Protein Array Analysis},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26041751}
}
EUVIMED